Analysts Issue Forecasts for BSX Q2 Earnings

Boston Scientific Co. (NYSE:BSX) – Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Boston Scientific in a note issued to investors on Monday, June 16th. Leerink Partnrs analyst M. Kratky forecasts that the medical equipment provider will post earnings per share of $0.73 for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Boston Scientific’s current full-year earnings is $2.85 per share. Leerink Partnrs also issued estimates for Boston Scientific’s Q3 2025 earnings at $0.72 EPS, Q4 2025 earnings at $0.73 EPS, Q1 2026 earnings at $0.79 EPS, Q2 2026 earnings at $0.82 EPS, Q3 2026 earnings at $0.84 EPS, Q4 2026 earnings at $0.90 EPS, FY2026 earnings at $3.36 EPS and FY2027 earnings at $3.88 EPS.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.08. The company had revenue of $4.66 billion during the quarter, compared to analysts’ expectations of $4.57 billion. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Boston Scientific’s revenue for the quarter was up 20.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.56 earnings per share.

Several other research analysts have also issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $115.00 price objective on shares of Boston Scientific in a research note on Wednesday, May 28th. Argus set a $130.00 price objective on Boston Scientific in a research note on Tuesday, February 18th. Morgan Stanley increased their price objective on Boston Scientific from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, May 16th. Leerink Partners initiated coverage on Boston Scientific in a research note on Monday. They issued an “outperform” rating and a $118.00 target price for the company. Finally, Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, April 29th. Twenty-two analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and a consensus price target of $116.09.

Boston Scientific Stock Up 1.8%

Shares of BSX stock opened at $101.49 on Tuesday. The stock has a market cap of $150.15 billion, a P/E ratio of 81.19, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. Boston Scientific has a one year low of $71.88 and a one year high of $107.17. The stock has a fifty day moving average price of $101.25 and a 200 day moving average price of $98.87. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 56,372 shares of the business’s stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $102.88, for a total value of $5,799,551.36. Following the sale, the executive vice president now owns 178,342 shares in the company, valued at approximately $18,347,824.96. The trade was a 24.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Vance R. Brown sold 4,826 shares of the business’s stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the sale, the senior vice president now owns 36,193 shares in the company, valued at $3,441,592.37. The trade was a 11.77% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 411,970 shares of company stock worth $42,406,693. Corporate insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in BSX. Colonial Trust Co SC increased its position in shares of Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 260 shares during the last quarter. Investment Management Corp VA ADV bought a new stake in shares of Boston Scientific during the 4th quarter valued at $25,000. Sunbeam Capital Management LLC bought a new stake in shares of Boston Scientific during the 4th quarter valued at $26,000. 1248 Management LLC bought a new stake in shares of Boston Scientific during the 1st quarter valued at $26,000. Finally, Y.D. More Investments Ltd bought a new stake in shares of Boston Scientific during the 1st quarter valued at $27,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.